Skip to content

Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy

Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01996397
Acronym
CCI impact
Enrollment
34
Registered
2013-11-27
Start date
2013-05-31
Completion date
2015-04-30
Last updated
2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment of Acute CRT Response, Heart Failure, Resynchronization Therapy

Keywords

Heart failure, Bundle branch block, CRT response

Brief summary

Exploratory, prospective, interventional, non-randomized single-center research study to compare metrics derived from 2 or 3-D reconstructions of lead movement, bioimpedance and VCG to augmentation of left ventricular contractility (LV dP/dt max) at different pacing configurations in patients undergoing a CRT-implant. Pacing sites and contractility data will be compared to pre operative cardiac ultrasound and MRI metrics.

Interventions

PROCEDURECardiac resynchronization therapy device implantation

Sponsors

Medtronic Cardiac Rhythm and Heart Failure
CollaboratorINDUSTRY
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is indicated for CRT or CRT-D device according to current applicable ESC/AHA guidelines * Subject is in stable sinus rhythm at the time of implant (no atrial arrhythmias lasting \> 30 seconds during the last 2 weeks prior to inclusion). No documented AF-episodes allowed during the last 2 weeks prior to inclusion. * Subject receives optimal heart failure oral medical therapy (ACE inhibitor and/or ARB and Beta Blockers), and is on a stable medication scheme for at least 2 months prior to enrollment. * Subject (or the legal guardian) is willing to sign informed consent form

Exclusion criteria

* Permanent atrial fibrillation/ flutter or tachycardia * RBBB * Recent myocardial infarction (MI), within 40 days prior to enrollment. Subject underwent coronary artery bypass graft (CABG) or valve surgery, within 90 days prior to enrollment * Post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year * Implanted with a left ventricular assist device (LVAD), or has reasonable probability (per investigator's discretion) of receiving a LVAD in the next year * On chronic renal dialysis, or with severe renal disease (defined as estimated Glomerular Filtration Rate (equation provided by Modification of Diet in Renal Disease study): (eGFR) \< 30 mL/min/1.73m2) * On continuous or uninterrupted infusion (inotropic) therapy for heart failure (≥ 2 stable infusions a week) * Severe aortic stenosis (with a valve area of \<1.0 cm2 or significant valve disease expected to be operated on within study period) * Complex and uncorrected congenital heart disease * Mechanical heart valve * Breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control * Enrolled in one or more concurrent studies that would confound the results of this study * Already implanted with pacemaker (CRT, CRT-D, ICD) and needs replacement

Design outcomes

Primary

MeasureTime frameDescription
dP\dt max response to different ventricular lead pacing sites6 monthsTo compare metrics derived from 2 or 3-D reconstructions of lead movement to augmentation of left ventricular contractility (LV dP/dt max) at different pacing configurations in patients undergoing a CRT-implant Main objective is to identify the optimal LV pacing site within each patient where the force of contraction during BiV pacing is maximized and to assess the feasibility of a non-invasive sensor to identify this optimal site.

Secondary

MeasureTime frameDescription
Lead movements and electrical measures6 monthsCompare metrics derived from 2/3-D reconstructions of lead movement to electrical measures (e.g. Q-LV-timing or VCG) at different pacing configurations in patients undergoing a CRT-implant.
Metrics derived from 2/3-D reconstructions of lead movement and Force-Interval-Relation6 monthsTo compare metrics derived from 2/3-D reconstructions of lead movement to Force-Interval-Relation at different pacing configurations in patients undergoing a CRT-implant.
Metrics derived from 2/3-D reconstructions of lead movement and CardioGuide Motion Map6 monthsTo compare metrics derived from 2/3-D reconstructions of lead movement to CardioGuide Motion Map at different pacing configurations in patients undergoing a CRT-implant.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026